Kishore Sirish A, Bajwa Raazi, Madoff David C
Department of Radiology, Division of Interventional Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Department of Radiology and Biomedical Imaging, Section of Interventional Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
Cancers (Basel). 2020 Mar 26;12(4):791. doi: 10.3390/cancers12040791.
Hepatocellular carcinoma (HCC) represents a significant contributor to cancer-related morbidity and mortality with increasing incidence in both developing and developed countries. Embolotherapy as a locoregional therapeutic strategy consists of trans-arterial or "bland" embolization (TAE), trans-arterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Trans-catheter arterial therapies can be applied along all stages of HCC, either as an alternative or neoadjuvant to surgical resection/transplantation in very early and early stage HCC or as a palliative option for local disease control in unresectable and advanced stage HCC. In advanced stage HCC, SIRT did not demonstrate superiority in comparison to systemic treatment options in several recent large prospective trials, though for carefully selected patients, may confer improved tolerability with similar disease control rates. The latest embolotherapeutic techniques and literature as they pertain to the management of HCC, as well as future directions, are reviewed in this article.
肝细胞癌（HCC）在发展中国家和发达国家的发病率均呈上升趋势，是导致癌症相关发病和死亡的重要因素。栓塞疗法作为一种局部治疗策略，包括经动脉或“单纯”栓塞（TAE）、经动脉化疗栓塞（TACE）和选择性内放射治疗（SIRT）。经导管动脉治疗可应用于HCC的各个阶段，在极早期和早期HCC中作为手术切除/移植的替代或新辅助治疗，或在不可切除的晚期HCC中作为局部疾病控制的姑息治疗选择。在晚期HCC中，在最近的几项大型前瞻性试验中，SIRT与全身治疗方案相比并未显示出优势，不过对于精心挑选的患者，SIRT可能在疾病控制率相似的情况下具有更好的耐受性。本文综述了与HCC治疗相关的最新栓塞治疗技术和文献，以及未来的发展方向。
